{"transactions":[{"id":725477,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35145,"kind":"person","name":"Dadoo Rajeev","position":1,"cik":"0001951685","reported_name":"Dadoo Rajeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:19:23.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-285521","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526285521/ownership.xml","form_type":"4"}},{"id":1100218,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35145,"kind":"person","name":"Dadoo Rajeev","position":1,"cik":"0001951685","reported_name":"Dadoo Rajeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:43:08.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-090944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025090944/ownership.xml","form_type":"4"}},{"id":1470703,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35145,"kind":"person","name":"Dadoo Rajeev","position":1,"cik":"0001951685","reported_name":"Dadoo Rajeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:06:22.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":7.73,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000950170-24-076867","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017024076867/ownership.xml","form_type":"4"}},{"id":1842711,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35145,"kind":"person","name":"Dadoo Rajeev","position":1,"cik":"0001951685","reported_name":"Dadoo Rajeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-29T01:03:55.000Z","date":"2023-06-27","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders,\nwhich date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-040115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123040115/doc4.xml","form_type":"4"}},{"id":2120029,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35145,"kind":"person","name":"Dadoo Rajeev","position":1,"cik":"0001951685","reported_name":"Dadoo Rajeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-10T23:00:15.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":3009677,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 2,546,473 shares of common stock of ARS Pharmaceuticals, Inc. (\"ARS\") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the \"Merger\"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are directly held by SR One Capital Fund II Aggregator, LP (\"SR One Fund II Aggregator\"). SR One Capital Partners II, LP (\"SR One Partners II\") serves as the general partner of SR One Fund II Aggregator and SR One Capital Management, LLC serves as the general partner of SR One Partners II. The Reporting Person is the managing partner of SR One Capital Management, LP, an entity affiliated with SR One Fund II Aggregator, and a limited partner of SR One Partners II. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":3009677,"source":{"system":"sec-edgar","filing":"0001209191-22-056439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056439/doc4.xml","form_type":"4"}}]}